NCT03740776 is a clinical trial in ST Elevation Myocardial Infarction, sponsored by Dongying Zhang.

Who is sponsoring NCT03740776?

NCT03740776 is sponsored by Dongying Zhang.

What condition does NCT03740776 study?

NCT03740776 studies ST Elevation Myocardial Infarction.

Is NCT03740776 still recruiting?

NCT03740776 is currently completed. Last updated 14 November 2018.

Last reviewed 2018-11-14 · How we verify

NCT03740776

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Eosinophils Percentage Predicts In-hospital Major Adverse Cardiac Events in STEMI Patients After PCI

Completed Last updated 14 November 2018

What this trial tests

trial in ST Elevation Myocardial Infarction in 2 participants. Completed in 1 November 2018.

Timeline

1 October 2015

Primary endpoint
1 August 2017

1 November 2018

Quick facts

Lead sponsor	Dongying Zhang
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2
Start date	1 October 2015
Primary completion	1 August 2017
Estimated completion	1 November 2018

Conditions studied

ST Elevation Myocardial Infarction — all drugs for ST Elevation Myocardial Infarction →

Sponsor

Dongying Zhang

Who can join

Adults 20 to 85, any sex, with ST Elevation Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Eosinophils (EOS) in peripheral blood are significantly decreased in ST-segment elevation myocardial infarction (STEMI) and the reduced EOS indicates severe myocardial damage. Whether EOS is a good predictor for in-hospital major adverse cardiac events (MACEs) of patients with ST-segment elevation myocardial infarction remains unknown. The aims of this study was to evaluate prognostic role of EOS for in-hospital MACEs in STEMI patients who have undergone primary percutaneous coronary intervention (PCI)

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Combination of eosinophil percentage and high-sensitivity C-reactive protein predicts in-hospital major adverse cardiac events in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.
Ye L, Bai HM, Jiang D, He B, et al · · 2020 · cited 6× · PMID 32441412 · DOI 10.1002/jcla.23367

Verify or expand the search:

Other recruiting trials for ST Elevation Myocardial Infarction

Currently open trials in the same condition.

NCT05785897 — STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT · NA · recruiting
NCT06795035 — Assessment of Coronary Microvascular Dysfunction After STEMI Using Continuous Saline Thermodilution · recruiting
NCT07058857 — The Effect of Low-Level Tragus Stimulation on Echocardiographic Parameters in Patients With ST-Segment Elevation Myocard · NA · recruiting
NCT06465303 — A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEM · Phase 2 · recruiting
NCT06535503 — Clinical Characteristics and Outcomes Among STEMI Patients With Cardiogenic Shock at Abu Dhabi City · recruiting

Other Dongying Zhang trials

Trials by the same sponsor.

NCT06812546 — Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction · Phase 4 · not yet recruiting
NCT06604611 — Colchicine in Patients With Heart Failure With Preserved Ejection Fraction and Inflammation · Phase 4 · not yet recruiting
NCT05068934 — The Relationship Between Epicardial Fat Tissue and Cardiac Function in HFpEF Patients · completed
NCT05059769 — Relationship Between Ambulatory Arterial Stiffness Index and Left Ventricular Diastolic Function in Patients With HFpEF · unknown
NCT06245980 — Role of SGLT2I in Patients With Myocardial Infarction · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03740776 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dongying Zhang
Last refreshed: 14 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03740776.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing